BeOne Medicines (ONC) Stock Analysis & Forecast

Nov 16 close

$411.29−5.25 (−1.3%)

Gekko Brief

Nov 16 close

BeOne Medicines closed at $411.29 on 16 November 2026, -1.3% on the day. The price sits above both the 50-day ($370.24) and 200-day ($328.15) moving averages, inside a 52-week range of $253.95 to $424.73. The GekkoIndex reads 47.9, in the Neutral zone, up 8.5 points over five sessions. Gekko Fair Value is $407.51, so the price is 0.9% above it.

The next earnings report is due on 25 February 2027, 100 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 4.6% across the report. Seasonally, the next 20 trading days from this point averaged -11.3% over the last 5 years, rising in 1 of them.

12 firms rate the stock: 12 buy, 0 hold and 0 sell, with a consensus target of $465.00. A typical daily move is about 3.3%, and a typical 20-day move about 9.8%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (seasonality).

A plain summary of the figures as of the Nov 16, 2026 close.

BeOne Medicines price vs fair value

$411.29$409.84Nov ’25May ’26Nov ’26
Close $411.29200-day averageGekko Fair Value $409.84

BeOne Medicines quick facts

Market cap
$43.95B
P/E ratio
52.7
Forward P/E
36.5
EPS, TTM
$7.80
Revenue, TTM
$6.61B
Profit margin
13.9%
Dividend yield
—
Beta
0.63
Volume
159,162 avg 440,628
1-year return
+11.7%
Typical daily move
±3.3%
Typical 20-day move
±9.8%
50-day average
$370.24
200-day average
$328.15
Next earnings
Feb 25 before open
Shares outstanding
105.4M
52-week range
$253.95$424.73

BeOne Medicines swing-trade checklist

BeOne Medicines scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $411.29 is above the 50-day ($370.24) and 200-day ($328.15) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    47.9, Neutral

    Reading 47.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.4% above

    Price is within 5% of Gekko Fair Value (0.4% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 25, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −10.9% on average

    From this point in the calendar, the next 20 trading days averaged −10.9% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

BeOne Medicines stock chart and price history

BeOne Medicines closed at $411.29 on Nov 16, 2026, +11.7% over the past year, inside a 52-week range of $253.95 to $424.73.

Close50-day average200-day averageVolume
BeOne Medicines share price, past year, with 50-day and 200-day moving averages and volume$300$350$400DecJan 2026FebMarAprMayJunJulAugSepOctNov411.29

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+11.4%
3 months
+11.4%
6 months
+40.3%
1 year
+11.7%
The full ONC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ONC in Gekko

Follow BeOne Medicines through every session

Put ONC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ONC in GekkoFree for 7 days. No credit card required.

About BeOne Medicines

BeOne Medicines focuses on finding and developing treatments for cancer patients, with reach into the United States, China, Europe and other regions. Its marketed products include BRUKINSA, a treatment for several blood cancers; TEVIMBRA, an immunotherapy used against various solid tumors and blood cancers; SYLVANT, for adults with multicentric castleman disease; BAITUOWEI, used in certain breast cancer cases; and PARTRUVIX, for various solid tumors.

Beyond these approved therapies, the company runs a broad pipeline of experimental compounds targeting different cancer pathways, alongside earlier-stage preclinical work. It has established agreements with other pharmaceutical companies, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis, reflecting collaborative ties across its research and development efforts.

The company was founded in 2010 and is headquartered in Basel, Switzerland. It previously operated under the name BeiGene, Ltd. before adopting its current name in May 2025. Its shares trade under the ticker ONC.

Sector
Health technology
Website
beonemedicines.com

BeOne Medicines GekkoIndex: the smart money zone

BeOne Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.9, in the Neutral zone, up 8.5 points over five sessions.

010047.9Neutral

Up 8.5 points over five sessions, from the Distribution zone.

Reading for Nov 16, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying43+2.4%+6.1%+10.4%+26.1%
Accumulation173+1.8%+4.5%+8.3%+14.4%
Neutral (current zone)346+0.7%+0.6%+1.2%+5.5%
Distribution84−0.2%0.0%+1.8%+2.1%
Selling14−0.7%−2.9%−4.3%−0.9%

Average ONC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ONC price, zone by zone.Track ONC in Gekko

Is BeOne Medicines stock overvalued? Gekko Fair Value

BeOne Medicines trades 0.4% above Gekko Fair Value of $409.84, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what BeOne Medicines shares are worth, recalculated every trading day.

$409.84

Gekko Fair Value, Nov 17, 2026

0.4% above fair value · About fair value

At the end of Aug 2026 the price was 9.0% below the estimate.

Gekko Fair ValueShare price, month end
$410$411Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ONC in Gekko

BeOne Medicines insider and Congress trading

No open-market insider purchases were filed for BeOne Medicines, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ONC in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ONC insider filing, plotted on the chart in Gekko.Open ONC in Gekko

Congress trades last 90 days

No trades in ONC were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ONC, plotted on the chart in Gekko.Open ONC in Gekko

BeOne Medicines earnings: next date and track record

BeOne Medicines reports on Feb 25, 2027, before the open (100 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+4.9%Feb ’25−2.4%May ’25−2.9%Aug ’25−0.4%Nov ’25−10.0%Feb ’26+6.6%May ’26+2.1%Aug ’26+7.7%Nov ’26

Last earnings call, Nov 5, 2026 AI summary

What they said
BeOne Medicines reported Q3 2026 BRUKINSA sales of $1.4 billion, up 34% year-over-year, with U.S. sales exceeding $1 billion for the first time. Real-world evidence across six independent datasets consistently favors BRUKINSA over ibrutinib and acalabrutinib in CLL, showing 16-36% lower mortality risk. The company highlighted a broadening hematology franchise with BEQALZI and tacabrutideg, while 2026 is described as an inflection year for solid tumors with five late-stage programs presenting differentiated data.
Guidance
CFO Aaron Rosenberg planned to provide updated 2026 financial guidance during the call. Management signaled continued rapid growth and strong earnings trajectory, with multiple pivotal trial readouts expected over the next three years across hematology and solid tumor programs.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 5, 2026$4.59
est $2.39
+92.1%$1.89B
est $1.76B
+7.5%+7.7%
Aug 5, 2026$2.05
est $1.40
+46.4%$1.71B
est $1.62B
+4.9%+2.1%
May 6, 2026$1.96
est $0.81
+142.0%$1.51B
est $1.48B
+2.5%+6.6%
Feb 26, 2026$0.58
est $1.60
−63.7%$1.50B
est $1.47B
+2.2%−10.0%
Nov 6, 2025$1.09
est $0.72
+51.4%$1.41B
est $1.45B
−2.7%−0.4%
Aug 6, 2025$0.84
est $0.48
+75.0%$1.32B
est $1.44B
−8.8%−2.9%
May 7, 2025$1.22
est −$0.71
+271.8%$1.12B
est $1.25B
−10.4%−2.4%
Feb 27, 2025−$1.43
est −$1.01
−41.6%$1.13B
est $1.04B
+8.5%+4.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

BeOne Medicines stock forecast and analyst price targets

Analysts’ average 12-month price target for BeOne Medicines is $469.23, +14.1% from the last close, from 12 firms rating the stock in the last 90 days.

$469.23consensus 12-month target, +14.1% from the last close
Low $430High $500.84
Buy12
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyBuy, maintained$476+15.7%
Nov 6BarclaysBuy, maintained$446+8.4%
Nov 6Citizens JMPBuy, maintained$463+12.6%
Nov 6Truist FinancialBuy, reiterated$448+8.9%
Nov 6Morgan StanleyBuy, maintained$465+13.1%
+1.2%average 20-day move after past Neutral readings
−10.9%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

BeOne Medicines seasonality: the next 20 trading days

Over the next 20 trading days from Nov 17, BeOne Medicines averaged −10.9% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−28.2%2021+2.2%2022−2.4%2023−4.6%2024−19.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−6.7%1 of 5
Next 10 trading days−3.0%2 of 5
Next 15 trading days−6.7%1 of 5
Next 20 trading days−10.9%1 of 5
Next 30 trading days−8.1%1 of 5

For scale, ONC’s typical 20-trading-day move in either direction is about 9.8%.

BeOne Medicines market cap and key statistics

BeOne Medicines’s market cap is $43.95B, with a P/E ratio of 52.7 and revenue of $6.61B over the last twelve months.

Valuation

Market cap
$43.95B
P/E ratio
52.7
Forward P/E
36.5
EPS, TTM
$7.80
Gekko Fair Value
$409.84

Trading

Volume
159,162
Avg volume, 20 days
440,628
52-week high
$424.73
52-week low
$253.95
Shares outstanding
105.4M

Financials

Revenue, TTM
$6.61B
Profit margin
13.9%
Return on equity
18.4%
Quarterly earnings growth, YoY
+212.5%

Risk and income

Beta
0.63
Typical daily move
±3.3%
Typical 20-day move
±9.8%

BeOne Medicines stock news this week

1 headline about BeOne Medicines from the past week, newest first, each linking to the publisher.

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

BeOne Medicines stock FAQ

What is BeOne Medicines’s market cap?

BeOne Medicines’s market cap is $43.95B at the Nov 16, 2026 close of $411.29, with 105.4M shares outstanding. The shares trade on a P/E ratio of 52.7.

What is the BeOne Medicines stock forecast?

The consensus analyst 12-month price target for BeOne Medicines is $469.23, +14.1% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is BeOne Medicines stock overvalued or undervalued?

On Gekko’s estimate BeOne Medicines is about fair value: the Nov 16, 2026 close of $411.29 is 0.4% above Gekko Fair Value of $409.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does BeOne Medicines report earnings next?

BeOne Medicines is expected to report on Feb 25, 2027, before the market opens (100 days away). Analysts expect earnings of $3.32 per share on revenue of $1.88B. BeOne Medicines beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.

What is BeOne Medicines’s 52-week high and low?

BeOne Medicines’s 52-week high is $424.73 and its 52-week low is $253.95; it closed at $411.29 on Nov 16, 2026, +11.7% over the past year.

Is BeOne Medicines stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See BeOne Medicines the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,476 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.